Because cancer TMN staging remained unknown during patient randomization and could be determined only after surgery, this may explain the difference in baseline HMGB1 levels between the two study groups, because more patients in the DEX group had cancer at an advanced stage. This evidence concerns the gene HMGB1 and cancer.